WGI

Session XXII: Colorectal Cancer: Metastatic Disease

Saturday, July 2, 2022

09:30 – 13:15

Location: Auditorium A; Level 0

Chair(s)

Eric Van Cutsem, MD, PhD

University Hospital Gasthuisberg/Leuven
Leuven, Belgium
Pia Osterlund, MD PhD Prof

Tampere university hospital and Karolinska Hospital/Institutet
Tampere, Finland

Presentations:

09:30 – 09:42

O-6: Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: results of the phase III randomized TRIPLETE study by GONO
Abstract Presenter: Daniele Rossini
09:42 – 10:02

Algorithms in First-Line and Second-Line Metastatic Disease
Speaker: Dirk Arnold, MD PhD – Asklepios Tumorzentrum Hamburg
10:02 – 10:14

O-7: Evidence of therapeutic effectiveness of III line cetuximab rechallenge in appropriately selected patients: finding from long-term follow-up of CRICKET and CAVE trials
Abstract Presenter: Erika Martinelli, MD, PhD – Università degli Studi della Campania Luigi Vanvitelli
10:14 – 10:34

Treatment Algorithms After Second-Line Metastatic Disease
Speaker: Fortunato Ciardiello, MD, PhD – Università degli Studi della Campania Luigi Vanvitelli
10:34 – 10:42

SO-37: Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib + cetuximab ± binimetinib: subanalysis of BEACON CRC
Abstract Presenter: Kimmie Ng
10:42 – 10:50

SO-38: Clinical efficacy and single cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
Abstract Presenter: Ryan Corcoran, MD PhD – MGH Cancer Center
10:50 – 11:02

O-8: Association of MSS/MSI-RNF43 molecular subtypes and clinical outcome of metastatic BRAF-V600E colorectal cancer patients treated with anti-BRAF/EGFR ± combinatorial therapies
Abstract Presenter: Rodrigo Toledo
11:02 – 11:22

Talks on Checkpoint Inhibitors in MSI-H Colorectal Cancer
Speaker: Thierry André, MD – Hopital Saint Antoine
11:22 – 11:42

How to Make MSS Tumors More Sensitive for Immunotherapy
Speaker: Ryan Corcoran, MD PhD – MGH Cancer Center
11:42 – 12:15

Break and Poster Viewing
12:15 – 12:35

BRAF Mutant Tumors: Strategy and New Data
Speaker: Scott Kopetz, MD, PhD – University of Texas MD Anderson Cancer Center
12:35 – 12:47

LBA-2: MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017)
Abstract Presenter: Jonathan Strickler, MD
12:47 – 12:55

SO-39: Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
Abstract Presenter: Hans Prenen
12:55 – 13:15

Rare Genomic Alterations Including Mutations and Fusions and Discussant
Speaker: Heinz-Josef Lenz, MD – University of Southern California